ENACT Project
ENACT aims to identify markers of response and tumour antigens that associate with breast, ovarian, prostate and melanoma progression and resistance to immunotherapy. In order to achieve this, prospective clinical material will be collected during the life time of the programme and new and existing tumour tissue, PBMC and serum banks will be available for use in the study. The material will be distributed to partners for the immunological, genomic, biochemical and proteomic analysis of tumour and host response(s) to immunotherapy. The results will be subjected to bioinformatics analysis in the context of clinical outcome of vaccine- based immunotherapy trials from 5 European Clinical Centres. Analysis of the results in the context of gender will allow prominent inter – and intra – tumour / host biomarkers to be identified for translation back into clinical practice.
The combined clinical and scientific expertise of the consortium provides added value and links with two 5th Framework cancer programmes that will allow immediate access to melanoma patient data, tumour tissue and cell lines.
[ Back to top ]